Pros | 3Y returns in the top 25% of the category. Beats FD returns for both 3Y & 5Y duration. | 5Y returns in the top 25% of the category. 3Y returns in the top 25% of the category. Among most bought funds within the category. | ||
Cons | - | - |
INDMoney rank | 6/8 | 2/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 12 Years | 7 Years | ||
Fund Size | 1125 Cr | 6437 Cr | ||
Min Investment | SIP ₹500 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 1.3% | 1.03% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 44 | 44 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (9.77%) Ajanta Pharma Ltd (6.25%) Lupin Ltd (5.58%) Glenmark Pharmaceuticals Ltd (4.12%) Cipla Ltd (3.74%) | Sun Pharmaceuticals Industries Ltd (11.88%) Dr Reddy's Laboratories Ltd (9.42%) Divi's Laboratories Ltd (8.5%) Aurobindo Pharma Ltd (7.62%) Cipla Ltd (6.61%) | ||
No of Sectors | 2 | 3 | ||
Top 3 Sectors | Health (98.9%) Basic Materials (1.1%) | Health (97.59%) Basic Materials (1.21%) Financial Services (1.2%) | ||
Equity % | 98.12% | 97.1% | ||
Debt % | - | - | ||
P/E | - | - | ||
P/B | - | - | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | -1.57% | -0.66% | ||
3-Month Return | -1.52% | 0.84% | ||
6-Month Return | 3.47% | 4.17% | ||
1-Year Return | -0.21% | 4.02% | ||
3-Year Return | 24.7% | 27.76% | ||
5-Year Return | 17.2% | 19.68% |
Sharpe | - | - | ||
Alpha | - | - | ||
Beta | - | - | ||
Standard Deviation | - | - | ||
Information Ratio | - | - |
Description | UTI Healthcare Fund-Growth Option- Direct is an equity fund.The fund could potentially beat inflation in the long-run. | ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Kamal Gada | Dharmesh Kakkad,Sharmila D’mello |